What has to be true before an unapproved drug leaves the country

The same question, asked in the opposite direction

Discussions about peptides and borders almost always run inbound: what a person may bring in, and what happens to a parcel.

The investigational drug rules answer the outbound question too, and the answer is more instructive. It shows what a regulator asks before an unproven substance is allowed to cross a border at all.

This is a different lane from a consumer parcel, and the distinction is worth keeping. What follows describes shipping an investigational drug, not what any particular seller does.

The ordinary route: a study at the other end

The first export route assumes the drug is going somewhere it will be studied, and it has three conditions.

An application must be in effect for the drug. The drug must comply with the laws of the country to which it is being exported.

And each person who receives the drug must be an investigator in a study submitted to and allowed to proceed under that application.

The pattern matches the domestic rules exactly. The substance moves between named people inside a supervised program, not into a general supply.

Two routes that turn on a named list of countries

The next two routes work differently. They rest on the drug's standing elsewhere, or on where it is going.

One applies where the drug has valid marketing authorization in Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, or in any country in the European Union or the European Economic Area.

The other applies where the drug is being exported to those same places. Both also require compliance with the laws of the destination country and with the statutory export provisions.

A small clause sits at the end of the second one. Drugs exported under it that are not the subject of an application are exempt from the investigational-use caution required on the immediate package.

That exemption is narrow and conditional, and it exists because the product is not being handled as an investigational drug on that route.

The certification route, and its eleven affirmations

The fourth route is the one worth reading slowly. It allows export on the strength of a written certification, sent at the time the drug is first exported.

The certification describes the drug, identifies the countries it is going to, and then affirms eleven things.

That the drug is intended for export. That it is intended for investigational use in a foreign country. That it meets the foreign purchaser's or consignee's specifications.

That it is not in conflict with the importing country's laws. That the outer shipping package is labeled to show the package is intended for export from the United States.

That the drug is not sold or offered for sale in the United States. That the clinical investigation will be conducted in accordance with the rules on foreign studies.

The last four affirmations, and where they point

The remaining four are about the product itself rather than the transaction.

That the drug is manufactured, processed, packaged and held in substantial conformity with current good manufacturing practices.

That the drug is not adulterated within the meaning of the specified provisions of the statute.

That it does not present an imminent hazard to public health, either in the United States if the drug were to be reimported, or in the foreign country.

And that the drug is labeled in accordance with the foreign country's laws.

The exporter also has to maintain records documenting compliance. The affirmation is not a one-time formality attached to a first shipment.

The reimportation clause

One phrase in that list deserves separate attention because of what it assumes.

The hazard affirmation covers the United States, if the drug were to be reimported, as well as the destination country.

The rule is anticipating that a substance sent abroad may come back. It therefore refuses to let an export be judged only by conditions at the far end.

That is a quietly realistic piece of drafting, and it is the mirror of what makes an overseas supply chain hard to reason about from a customer's side.

What an emergency changes, and what it does not

The certification route bends for a national emergency in the destination country, in two defined situations.

Where an investigational drug is to be stockpiled in anticipation of an emergency, the exporter may omit some of the affirmations. Doing so requires a written statement explaining why compliance is not feasible or is contrary to the best interests of the people who may receive the drug.

It also requires a written statement from an authorized official of the importing country's government agreeing with that explanation, describing the potential emergency, and confirming the drug is for that purpose alone.

And a further written statement showing that the Secretary of Health and Human Services, or a designee, agrees with the findings. Export may not proceed until the agency has authorized it.

Where the emergency has already developed or is developing, a similar set of omissions is available and export may proceed without prior authorization. The written statements are still required.

So the emergency provisions relax the paperwork sequence. They never remove the requirement that a named official in the receiving country stands behind the request.

The conditions that switch a permission off

None of the four routes is permanent, and the rule lists what ends each.

For the study route, export may not occur once the application covering the investigation is no longer in effect.

For the two country-list routes, it ends when the statutory conditions they rest on are no longer met.

For the certification route, it ends when the conditions underlying the certification, or the emergency statements, are no longer met.

And one condition applies to every route at once. Export may not occur where the drug no longer complies with the laws of the importing country.

A permission tied to a foreign law therefore expires when that foreign law changes, without anything happening at this end.

The inbound paragraph, in one line

The same section handles imports, and the rule is short.

An investigational drug offered for import complies where an application is in effect for it. The recipient in the United States must be one of three parties. The sponsor, a qualified investigator named in the application, or an identified domestic agent of a foreign sponsor.

That paragraph is covered in a companion article on who carries the duties in a trial, and the consumer import question is covered separately again.

Reading the list from the other direction

The eleven affirmations are the most useful part of this section for someone outside the system, because they read as a checklist of what a regulator wants settled before an unproven substance travels.

Where it is going, and under whose law. Whether anyone is selling it domestically. Whether it was made under recognized manufacturing practice.

Whether it is adulterated. Whether it would be hazardous if it came back. How it is labeled at the far end, and how the outer package is marked.

A parcel arriving from an overseas seller sits in a different legal lane, and none of these affirmations belongs to it. That is exactly why the list is worth knowing.

It gives a reader a concrete set of questions rather than a general unease, and each one has a checkable answer or a visible silence.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 312.110 — Import and export requirements — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026